Meiji Pharmaceutical University · Unclassified

Research keywordshematologic pharmacotherapy・multiple myeloma・lenalidomide skin rash・venetoclax drug interactions・gilteritinib pharmacokinetics・pneumocystis pneumonia・COVID-19 vaccination response・therapeutic drug monitoring

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia.2024 · Ann Hematol. 2024 Nov;103(11):4497-4502.
• Prevention of pneumocystis pneumonia in patients with hematological diseases: Efficacy of low-dose atovaquone.2023 · Int J Clin Pharmacol Ther. 2023 Nov;61(11):515-519.
• Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash.2022 · J Clin Pharm Ther. 2022 Apr;47(4):477-482.
• 腎機能低下患者へのボルテゾミブ投与時の帯状疱疹予防におけるアシクロビル隔日投与の有効性の検討

• Official profile